Semaglutide Reduces Major Cardiovascular Events by 20% in SELECT Trial
The landmark SELECT trial demonstrated that weekly semaglutide 2.4mg significantly reduced the risk of heart attack, stroke, and cardiovascular death in overweight adults without diabetes, establishing a new standard of care.
Tirzepatide Achieves 22.5% Body Weight Reduction in SURMOUNT-1 Phase 3 Trial
SURMOUNT-1 Phase 3 data confirms tirzepatide's unprecedented efficacy for obesity treatment. At the highest dose (15mg), 57% of participants achieved at least 20% weight loss over 72 weeks.
GLP-1 Agonists Outperform Insulin in Long-Term HbA1c Control for Type 2 Diabetes
A 5-year comparative effectiveness study found GLP-1 receptor agonists achieved superior glycemic control with fewer hypoglycemic episodes compared to basal insulin in type 2 diabetes patients.
GLP-1 Receptors in the Brain: New Evidence for Neuroprotective Effects
Emerging research reveals GLP-1 receptors are widely expressed in the brain, with preclinical and early clinical data suggesting neuroprotective effects relevant to Alzheimer's, Parkinson's, and addiction disorders.
Long-Term Safety Profile of GLP-1 Agonists: 10-Year Real-World Data
A comprehensive real-world analysis of over 500,000 patients on GLP-1 therapy for up to 10 years confirms a favorable safety profile, with no increased risk of pancreatitis, thyroid cancer, or major organ toxicity.
Telehealth GLP-1 Prescribing: Outcomes Equivalent to In-Person Care
A randomized controlled trial comparing telehealth vs. in-person GLP-1 prescribing found equivalent weight loss outcomes, adherence rates, and safety profiles, validating remote prescribing models.